Bristol-Myers Squibb (NYSE:BMY – Get Free Report) had its target price dropped by stock analysts at BMO Capital Markets from $55.00 to $48.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 6.48% from the stock’s current price.
Several other research analysts have also commented on the company. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $60.00.
Check Out Our Latest Stock Analysis on BMY
Bristol-Myers Squibb Price Performance
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter in the previous year, the company posted $2.05 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.
Hedge Funds Weigh In On Bristol-Myers Squibb
Hedge funds have recently modified their holdings of the business. OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth $25,000. Milestone Investment Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth $27,000. Northwest Financial Advisors acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $27,000. Blue Bell Private Wealth Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares during the period. Finally, Accordant Advisory Group Inc acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $31,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Bristol-Myers Squibb
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Stocks Leading the U.S. Agriculture Comeback
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Investing in the High PE Growth Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.